Continuing velzatinib for people with GIST who are already taking it
Part of Cancer, Digestive system clinical trials.
This study lets people with GIST who are already benefiting from velzatinib in another trial continue taking it. The goal is to keep providing the drug while researchers gather more information on its long-term effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must already be taking velzatinib for GIST in another clinical study.
- Your doctor must agree that you are getting benefit from velzatinib.
- You must not have stopped velzatinib permanently for any reason.
- You cannot have started any other cancer treatment since your last dose on the parent study.
- You must be willing to follow study visits and procedures, and give written consent.
- If you could become pregnant (or have a partner who could), you must use highly effective birth control or avoid sex during treatment and for 30 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill called velzatinib for people with GIST that has spread or can't be removed by surgery, after other treatments have stopped working. It may help shrink the tumor or slow its growth.
This program offers early access to an investigational drug called velzatinib for people with advanced GIST that has a KIT mutation. It is for patients who have run out of standard treatment options and cannot join other clinical trials.
This trial compares a newer cancer drug (velzatinib) with a standard treatment (imatinib) for gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have spread. You would receive one of these two drugs to see which works better and is safer.
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
This trial gives patients with advanced GIST access to the investigational drug bezuclastinib combined with sunitinib. It is for people who have already tried imatinib and need another option.
This trial tests a drug called lenvatinib for people with advanced GIST that has not responded to three previous treatments. It may offer a new option if standard therapies have stopped working or caused severe side effects.
Hear when a new Gastrointestinal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.